Tuberculosis Research Program, Centenary Institute, Newtown, NSW, Australia.
Eur J Immunol. 2015 Mar;45(3):780-93. doi: 10.1002/eji.201444954. Epub 2014 Dec 23.
Tuberculosis remains a global health problem, in part due to failure of the currently available vaccine, BCG, to protect adults against pulmonary forms of the disease. We explored the impact of pulmonary delivery of recombinant influenza A viruses (rIAVs) on the induction of Mycobacterium tuberculosis (M. tuberculosis)-specific CD4(+) and CD8(+) T-cell responses and the resultant protection against M. tuberculosis infection in C57BL/6 mice. Intranasal infection with rIAVs expressing a CD4(+) T-cell epitope from the Ag85B protein (PR8.p25) or CD8(+) T-cell epitope from the TB10.4 protein (PR8.TB10.4) generated strong T-cell responses to the M. tuberculosis-specific epitopes in the lung that persisted long after the rIAVs were cleared. Infection with PR8.p25 conferred protection against subsequent M. tuberculosis challenge in the lung, and this was associated with increased levels of poly-functional CD4(+) T cells at the time of challenge. By contrast, infection with PR8.TB10.4 did not induce protection despite the presence of IFN-γ-producing M. tuberculosis-specific CD8(+) T cells in the lung at the time of challenge and during infection. Therefore, the induction of pulmonary M. tuberculosis epitope-specific CD4(+), but not CD8(+) T cells, is essential for protection against acute M. tuberculosis infection in the lung.
结核病仍然是一个全球性的健康问题,部分原因是目前可用的卡介苗(BCG)疫苗未能保护成年人免受肺部疾病的侵害。我们探讨了肺部递送重组流感 A 病毒(rIAV)对诱导结核分枝杆菌(M. tuberculosis)特异性 CD4(+)和 CD8(+)T 细胞反应的影响,以及由此对 C57BL/6 小鼠结核分枝杆菌感染的保护作用。用表达 Ag85B 蛋白 CD4(+)T 细胞表位(PR8.p25)或 TB10.4 蛋白 CD8(+)T 细胞表位(PR8.TB10.4)的 rIAV 鼻内感染,在肺部引发针对结核分枝杆菌特异性表位的强烈 T 细胞反应,这些反应在清除 rIAV 后很长时间内仍持续存在。用 PR8.p25 感染可预防随后在肺部发生结核分枝杆菌的挑战感染,这与在挑战时和感染期间增加多功能 CD4(+)T 细胞的水平有关。相比之下,尽管在挑战时和感染期间肺部存在产生 IFN-γ的结核分枝杆菌特异性 CD8(+)T 细胞,但用 PR8.TB10.4 感染不能诱导保护作用。因此,诱导肺部结核分枝杆菌表位特异性 CD4(+),而不是 CD8(+)T 细胞,是预防肺部急性结核分枝杆菌感染所必需的。